A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2002
10/03/2002	WO2002076400A2 Inosine compounds and their use for treating or preventing an inflamation or a reperfusion disease
10/03/2002	WO2002076397A2 Telomerase inhibitors and methods of their use
10/03/2002	WO2002076396A2 Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
10/03/2002	WO2002076395A2 Agents and methods for treatment of cancer
10/03/2002	WO2002076394A2 Enzyme-based anti-cancer compositions and methods
10/03/2002	WO2002076393A2 Antiagionecic, antitumor, chemopreventative agents
10/03/2002	WO2002076389A2 Compositions and methods to prevent metastasis from primary malignancies
10/03/2002	WO2002076384A2 Therapeutic compositions that alter the immune response
10/03/2002	WO2002076381A2 Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
10/03/2002	WO2002076380A2 Cytotoxic factors for modulating cell death
10/03/2002	WO2002076216A1 Viral vectors and their use in therapeutic methods
10/03/2002	WO2002076173A2 Inhibitors of glycosaminoglycans
10/03/2002	WO2002062794A3 Compounds
10/03/2002	WO2002062359B1 Preparation of cartilage extracts using organic solvents
10/03/2002	WO2002062293A3 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
10/03/2002	WO2002060276A9 Combination of probiotics
10/03/2002	WO2002058728A3 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
10/03/2002	WO2002055533A3 Methods of using imxp-888 and imxp-888 antagonists
10/03/2002	WO2002046226A3 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
10/03/2002	WO2002045590A9 Method for regional administeration of preparations for curing liver tumors
10/03/2002	WO2002030942A3 Anhydro sugar derivatives of indolocarbazoles
10/03/2002	WO2002030941A3 Topoisomerase inhibitors
10/03/2002	WO2002029086A3 Nucleic acid sequences differentially expressed in cancer tissue
10/03/2002	WO2002026193A3 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
10/03/2002	WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002	WO2002018407A3 Antisense oligonucleotides against vanilloid receptor 1
10/03/2002	WO2002014349A3 Non-covalent inhibitors of urokinase and blood vessel formation
10/03/2002	WO2002012188A3 Indole compounds useful for the treatment of cancer
10/03/2002	WO2002009744A3 Modified sialic acid vaccines
10/03/2002	WO2002004949A3 Reagents and methods for identification of binding agents
10/03/2002	WO2002002751A3 Alteration of cell membrane
10/03/2002	WO2002000242A3 Human papilloma virus treatment
10/03/2002	WO2001096388A3 Compositions and methods for the therapy and diagnosis of colon cancer
10/03/2002	WO2001093836A3 Encapsulation of polynucleotides and drugs into targeted liposomes
10/03/2002	WO2001087306A8 Compositions and methods for the treatment of colorectal cancer
10/03/2002	WO2001076603A1 Medicinal compositions containing camptothecin derivative and ph regulating agent
10/03/2002	WO2001071004A3 Proteases
10/03/2002	WO2001021812A9 Phosphatases which activate map kinase pathways
10/03/2002	WO2001019846A9 Transgenically produced fusion proteins
10/03/2002	WO2001019800A9 Mediators of hedgehog signaling pathways, compositions and uses related thereto
10/03/2002	WO2001017508A9 Cationic liposome delivery of taxanes to angiogenic blood vessels
10/03/2002	US20020143182 For therapy of diseases having uncontrolled cellular proliferation
10/03/2002	US20020143149 Seven trans-membrane receptor-Fitz2
10/03/2002	US20020143066 Perylenequinones for use as photosensitizers and sonosensitizers
10/03/2002	US20020143064 Inhibiting vascularization of a tumor mass by administering chalcone compound
10/03/2002	US20020143062 Admixing retinoid or a derivative with dimyristoyl phosphatidylcholine, soybean oil, tertiarybutyl alcohol and water to produce mixture
10/03/2002	US20020143055 Administering an effective amount of propionoyloxymethyl propionate, butyroyloxymethyl butyrate, or mixtures for therapy of illness
10/03/2002	US20020143043 For therapy and prophylaxis of rheumatoid arthritis, or of allergic disorders, asthma, inflammation; inhibitors of the adhesion and migration of leucocytes and/or antagonists of adhesion receptor VLA-4 belonging to the integrins group
10/03/2002	US20020143038 Parenteral formulation for epothilone analogs
10/03/2002	US20020143032 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
10/03/2002	US20020143026 Induce mitotic arrest thereby making them useful as anti-cancer agents; also for therapy of diseases which can be treated by inducing mitotic arrest
10/03/2002	US20020143021 Administering to vertebrate an effective tumor-growth-inhibiting phenylahistin compound or prodrug ester for therapy of cancer
10/03/2002	US20020142996 Use of bisphosphonic acids for treating angiogenesis
10/03/2002	US20020142989 Oncolytic/immunogenic complementary-adenoviral vector system
10/03/2002	US20020142988 G-coupled receptor showing selective affinity for ATP
10/03/2002	US20020142985 Therapeutic compositions and methods of treating glycolipid storage related disorders
10/03/2002	US20020142980 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
10/03/2002	US20020142966 For cancer therapy
10/03/2002	US20020142962 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
10/03/2002	US20020142960 Exposing cells to an aggregate formulation which comprises VP22, or a polypeptide with transport function of VP22, and oligonucleotides or polynucleotides; exposing cells to a disaggregating agent which can promote disaggregation
10/03/2002	US20020142943 A drug and an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine residue of p100 and/or p120, wherein the ability of the drug to cross a physiological barrier is improved.
10/03/2002	US20020142941 Intraductal treatment targeting methylated promoters in breast cancer
10/03/2002	US20020142448 Antibody for use in the diagnosis, treatment and prevention of bone disorders and cancer
10/03/2002	US20020142442 Tumor suppressor WAF1
10/03/2002	US20020142436 Enzymatic protein for use in the treatment of tumors, nervous system, cardiovascular, psychological, pregnancy, bone, kidney, respiratory and alimentary canal disorders
10/03/2002	US20020142430 Peptide for use in the treatment of inflammation, cancer, arteriosclerosis and psoriasis
10/03/2002	US20020142392 Human melanocyte stimulating hormone receptor polypeptide and DNA
10/03/2002	US20020142359 Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
10/03/2002	US20020142358 Antibody for use in the diagnosis, prevention and treatment of infections, multiple sclerosis, arthritis, autoimmune, inflammation and graft versus host disease
10/03/2002	US20020142357 TNF receptor action modulation
10/03/2002	US20020142348 Protein-protein interactions and methods for identifying interacting proteins and the amino acid sequence at the site of interaction
10/03/2002	US20020142282 Immortalized human keratinocyte cell line
10/03/2002	US20020142045 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
10/03/2002	US20020142007 Intracellular delivery vehicles
10/03/2002	US20020142005 Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
10/03/2002	US20020141993 Apoptosis; anticancer agents
10/03/2002	US20020141991 Methods of treating inflammatory disease using antibodies which bind GPR-9-6
10/03/2002	US20020141978 Retroviral vectors
10/03/2002	US20020141971 Administering by tissue absorption
10/03/2002	US20020141970 Stabilized with chelate compound; storage stability
10/03/2002	US20020141966 Compositions for treatment of malignant effusions, and methods of making and using the same
10/03/2002	US20020141941 PSCA: prostate stem cell antigen and uses thereof
10/03/2002	CA2783647A1 Histone deacetylase inhibitors
10/03/2002	CA2692295A1 Combined use of methylol-transfer agents and fas-ligands in the treatment of cancer
10/03/2002	CA2664797A1 Cytotoxic factors for modulating cell death
10/03/2002	CA2442318A1 Antibodies against cancer
10/03/2002	CA2442089A1 Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
10/03/2002	CA2442080A1 A preparation for restenosis prevention
10/03/2002	CA2442012A1 Chemical derivatives and their use as anti-telomerase agent
10/03/2002	CA2441933A1 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity
10/03/2002	CA2441806A1 Inosine compounds and their use for treating or preventing an inflammation or a reperfusion disease
10/03/2002	CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
10/03/2002	CA2441768A1 Method for treatment of cancer and compositions for use therein
10/03/2002	CA2441706A1 A new essential downstream component of the wingless signalling pathway
10/03/2002	CA2441663A1 Viral vectors and their use in therapeutic methods
10/03/2002	CA2441599A1 Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
10/03/2002	CA2441568A1 Pharmaceutical combinations for the treatment of cancer
10/03/2002	CA2441484A1 Molecular conjugates for use in treatment of cancer
10/03/2002	CA2441412A1 Topoisomerase i selective cytotoxic sugar derivatives of indolopyrrolocarbazoles
10/03/2002	CA2441394A1 Agents and methods for treatment of cancer

1 ... 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 ... 2211